Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
- Resource Type
- Article
- Authors
- Kennedy, Nicholas A.; Simeng Lin; Goodhand, James R.; Chanchlani, Neil; Hamilton, Benjamin; Bewshea, Claire; Nice, Rachel; Chee, Desmond; Cummings, J. R. Fraser; Fraser, Aileen; Irving, Peter M.; Kamperidis, Nikolaos; Kok, Klaartje B.; Lamb, Christopher Andrew; Macdonald, Jonathan; Mehta, Shameer; Pollok, Richard C. G.; Raine, Tim; Smith, Philip J.; Verma, Ajay Mark
- Source
- Gut; Oct2021, Vol. 70 Issue 10, p1884-1893, 10p
- Subject
- MEDICAL personnel
COVID-19 vaccines
SARS-CoV-2
INFLIXIMAB
MEDICAL research
INTESTINAL diseases
- Language
- ISSN
- 00175749